|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/70 | (2006.01) |
| A61P 31/12 | (2006.01) |
| (11) | Number of the document | 4188389 |
| (13) | Kind of document | T |
| (96) | European patent application number | 21716724.6 |
| Date of filing the European patent application | 2021-04-01 | |
| (97) | Date of publication of the European application | 2023-06-07 |
| (45) | Date of publication and mention of the grant of the patent | 2025-09-17 |
| (46) | Date of publication of the claims translation | 2025-11-10 |
| (86) | Number | PCT/EP2021/058727 |
| Date | 2021-04-01 |
| (87) | Number | WO 2022/022865 |
| Date | 2022-02-03 |
| (30) | Number | Date | Country code |
| 202063057139 P | 2020-07-27 | US | |
| 202063070869 P | 2020-08-27 | US | |
| 202063082524 P | 2020-09-24 | US | |
| 202063093961 P | 2020-10-20 | US | |
| 202063119711 P | 2020-12-01 | US | |
| 202163152445 P | 2021-02-23 | US | |
| 202163161629 P | 2021-03-16 | US |
| (72) |
LANGKILDE, Anna Maria , SE
|
| (73) |
AstraZeneca AB ,
151 85 Södertälje,
SE
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Dapagliflozinas, skirtas panaudoti taikant lėtinės inkstų ligos gydymo būdą |
| DAPAGLIFLOZIN FOR USE IN METHODS OF TREATING CHRONIC KIDNEY DISEASE |
| Payment date | Validity (years) | Amount | |
| 2026-03-19 | 6 | 139.00 EUR |
| 2027-04-01 |